Abstract：Bacterial antibiotic resistance is a worldwide challenge in 21st century. As antibiotic resistance becomes more and more serious, macromolecular monoclonal antibodies and the related targeting drugs are expected to be the next generation treatments. Antibody-antibiotic conjugates (AAC), similar to antibody-drug conjugates (ADC) in tumor therapy, are new types of drugs that are able to treat resistant bacteria infections, taking the advantage of both monoclonal antibody and antibiotics. This paper briefly reviewed the research advances in the development of AACs, as well as the progress in its three components: bacteria targeting monoclonal antibody, the antibiotic payload and the linker which was crucial for the AAC functions.
